A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer.
Exploratory analyses of the POTOMAC phase III trial showed adding one year of treatment with AstraZeneca’s Imfinzi (durvalumab) to BCG induction and maintenance therapy reduced the number of high-risk disease recurrences within the first year, with fewer BCG-unresponsive recurrences in patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer compared to BCG treatment alone.
